Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma

M. L. Byrum, H. C. Pondenis, R. L. Fredrickson, K. L. Wycislo, T. M. Fan

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The establishment and progression of metastases remains the life-limiting factor for dogs diagnosed with osteosarcoma (OS). The pattern of metastases is likely regulated through interactions between chemokine receptors and chemokines, and perturbations in these signaling cascades responsible for cytoskeletal organization and directional migration have the potential to alter metastatic cell trafficking behaviors.

HYPOTHESIS: Zoledronate will impair directional migration of OS cells through downregulation of chemokine (C-X-C motif) receptor 4 (CXCR4) expression and functionality.

SAMPLES: Nineteen archived tumor specimens and plasma from 20 dogs with OS.

METHODS: Prospectively, the expressions of CXCR4 were studied in OS cell lines and spontaneous tumor samples. The effect of zoledronate on CXCR4 expression and functionality was investigated by characterizing responses in 3 OS cell lines. In 19 OS specimens and 20 dogs with OS, changes in CXCR4 expression and circulating CXCR4 concentrations were characterized in response to zoledronate therapy respectively.

RESULTS: All canine OS cells express CXCR4, and zoledronate reduces CXCR4 expression and functionality by 27.7% (P < .0001), through augmented proteasome degradation and reduced prenylation of heterotrimeric G-proteins in 33% of tumor cell lines evaluated. In OS-bearing dogs, zoledronate reduces CXCR4 expressions by 40% within the primary tumor compared to untreated controls (P = .03) and also decreases the circulating concentrations of CXCR4 in 18 of 20 dogs with OS.

CONCLUSIONS AND CLINICAL IMPORTANCE: Zoledronate can alter CXCR4 expression and functionality in OS cells, and consequent perturbations in CXCR4 intracellular signaling cascades might influence patterns of metastases.

Original languageEnglish (US)
Pages (from-to)1187-1196
Number of pages10
JournalJournal of veterinary internal medicine
Volume30
Issue number4
DOIs
StatePublished - Jul 1 2016

Fingerprint

zoledronic acid
osteosarcoma
Osteosarcoma
Canidae
Down-Regulation
receptors
dogs
Dogs
metastasis
cell lines
Neoplasm Metastasis
Tumor Cell Line
neoplasms
CCR Receptors
cells
Prenylation
Heterotrimeric GTP-Binding Proteins

Keywords

  • Aminobisphosphonate
  • Cell chemotaxis
  • Pattern of metastases

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma. / Byrum, M. L.; Pondenis, H. C.; Fredrickson, R. L.; Wycislo, K. L.; Fan, T. M.

In: Journal of veterinary internal medicine, Vol. 30, No. 4, 01.07.2016, p. 1187-1196.

Research output: Contribution to journalArticle

@article{e6121b27ae374e2b902df7e8c5f03b91,
title = "Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma",
abstract = "BACKGROUND: The establishment and progression of metastases remains the life-limiting factor for dogs diagnosed with osteosarcoma (OS). The pattern of metastases is likely regulated through interactions between chemokine receptors and chemokines, and perturbations in these signaling cascades responsible for cytoskeletal organization and directional migration have the potential to alter metastatic cell trafficking behaviors.HYPOTHESIS: Zoledronate will impair directional migration of OS cells through downregulation of chemokine (C-X-C motif) receptor 4 (CXCR4) expression and functionality.SAMPLES: Nineteen archived tumor specimens and plasma from 20 dogs with OS.METHODS: Prospectively, the expressions of CXCR4 were studied in OS cell lines and spontaneous tumor samples. The effect of zoledronate on CXCR4 expression and functionality was investigated by characterizing responses in 3 OS cell lines. In 19 OS specimens and 20 dogs with OS, changes in CXCR4 expression and circulating CXCR4 concentrations were characterized in response to zoledronate therapy respectively.RESULTS: All canine OS cells express CXCR4, and zoledronate reduces CXCR4 expression and functionality by 27.7{\%} (P < .0001), through augmented proteasome degradation and reduced prenylation of heterotrimeric G-proteins in 33{\%} of tumor cell lines evaluated. In OS-bearing dogs, zoledronate reduces CXCR4 expressions by 40{\%} within the primary tumor compared to untreated controls (P = .03) and also decreases the circulating concentrations of CXCR4 in 18 of 20 dogs with OS.CONCLUSIONS AND CLINICAL IMPORTANCE: Zoledronate can alter CXCR4 expression and functionality in OS cells, and consequent perturbations in CXCR4 intracellular signaling cascades might influence patterns of metastases.",
keywords = "Aminobisphosphonate, Cell chemotaxis, Pattern of metastases",
author = "Byrum, {M. L.} and Pondenis, {H. C.} and Fredrickson, {R. L.} and Wycislo, {K. L.} and Fan, {T. M.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/jvim.14257",
language = "English (US)",
volume = "30",
pages = "1187--1196",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma

AU - Byrum, M. L.

AU - Pondenis, H. C.

AU - Fredrickson, R. L.

AU - Wycislo, K. L.

AU - Fan, T. M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - BACKGROUND: The establishment and progression of metastases remains the life-limiting factor for dogs diagnosed with osteosarcoma (OS). The pattern of metastases is likely regulated through interactions between chemokine receptors and chemokines, and perturbations in these signaling cascades responsible for cytoskeletal organization and directional migration have the potential to alter metastatic cell trafficking behaviors.HYPOTHESIS: Zoledronate will impair directional migration of OS cells through downregulation of chemokine (C-X-C motif) receptor 4 (CXCR4) expression and functionality.SAMPLES: Nineteen archived tumor specimens and plasma from 20 dogs with OS.METHODS: Prospectively, the expressions of CXCR4 were studied in OS cell lines and spontaneous tumor samples. The effect of zoledronate on CXCR4 expression and functionality was investigated by characterizing responses in 3 OS cell lines. In 19 OS specimens and 20 dogs with OS, changes in CXCR4 expression and circulating CXCR4 concentrations were characterized in response to zoledronate therapy respectively.RESULTS: All canine OS cells express CXCR4, and zoledronate reduces CXCR4 expression and functionality by 27.7% (P < .0001), through augmented proteasome degradation and reduced prenylation of heterotrimeric G-proteins in 33% of tumor cell lines evaluated. In OS-bearing dogs, zoledronate reduces CXCR4 expressions by 40% within the primary tumor compared to untreated controls (P = .03) and also decreases the circulating concentrations of CXCR4 in 18 of 20 dogs with OS.CONCLUSIONS AND CLINICAL IMPORTANCE: Zoledronate can alter CXCR4 expression and functionality in OS cells, and consequent perturbations in CXCR4 intracellular signaling cascades might influence patterns of metastases.

AB - BACKGROUND: The establishment and progression of metastases remains the life-limiting factor for dogs diagnosed with osteosarcoma (OS). The pattern of metastases is likely regulated through interactions between chemokine receptors and chemokines, and perturbations in these signaling cascades responsible for cytoskeletal organization and directional migration have the potential to alter metastatic cell trafficking behaviors.HYPOTHESIS: Zoledronate will impair directional migration of OS cells through downregulation of chemokine (C-X-C motif) receptor 4 (CXCR4) expression and functionality.SAMPLES: Nineteen archived tumor specimens and plasma from 20 dogs with OS.METHODS: Prospectively, the expressions of CXCR4 were studied in OS cell lines and spontaneous tumor samples. The effect of zoledronate on CXCR4 expression and functionality was investigated by characterizing responses in 3 OS cell lines. In 19 OS specimens and 20 dogs with OS, changes in CXCR4 expression and circulating CXCR4 concentrations were characterized in response to zoledronate therapy respectively.RESULTS: All canine OS cells express CXCR4, and zoledronate reduces CXCR4 expression and functionality by 27.7% (P < .0001), through augmented proteasome degradation and reduced prenylation of heterotrimeric G-proteins in 33% of tumor cell lines evaluated. In OS-bearing dogs, zoledronate reduces CXCR4 expressions by 40% within the primary tumor compared to untreated controls (P = .03) and also decreases the circulating concentrations of CXCR4 in 18 of 20 dogs with OS.CONCLUSIONS AND CLINICAL IMPORTANCE: Zoledronate can alter CXCR4 expression and functionality in OS cells, and consequent perturbations in CXCR4 intracellular signaling cascades might influence patterns of metastases.

KW - Aminobisphosphonate

KW - Cell chemotaxis

KW - Pattern of metastases

UR - http://www.scopus.com/inward/record.url?scp=84971614232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971614232&partnerID=8YFLogxK

U2 - 10.1111/jvim.14257

DO - 10.1111/jvim.14257

M3 - Article

C2 - 27251585

AN - SCOPUS:84971614232

VL - 30

SP - 1187

EP - 1196

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 4

ER -